The STAPLE International Post-Market Registry

Inclusion Criteria: 1. Patient ≥ 18 years old 2. Patient has given written informed consent 3. Patient has a life expectancy \> 1 year 4. Patient is willing to comply with follow-up evaluations 5. Patient's AAA meets at least one of the following criteria: * ≥ 4.5cm in diameter * Increased in size by 0.5cm in last 6 months * Maximum diameter exceeds 1.5 times the transverse dimension of an adjacent normal aortic segment * Saccular aneurysm larger than 3cm in maximal diameter 6. Patient has a proximal aortic neck diameter measured inner wall to inner wall between 19mm and 29mm 7. Patient has a proximal aortic neck length of at least 12mm 8. Patient has a patent iliac or femoral artery that allows endovascular access to the aneurysmal site with 16Fr (5.3mm) or 18Fr (6.0mm) delivery system. 9. Patient has bilateral iliac artery distal fixation site ≥ 10mm in length with an internal diameter between 9mm and 20mm Exclusion Criteria: 1. Patient is participating in a concurrent clinical study which may confound STAPLE-International Registry results 2. Patient has a symptomatic AAA 3. Patient's AAA has a proximal aortic neck angle that is \> 60 degrees between the infrarenal neck and the long axis of the aneurysm 4. Patient has irregularly-shaped plaque that would inhibit sealing stent apposition 5. Patient has aortic mural pathology that is ≥ 2mm in thickness over ≥ 50% of the circumference of the proximal fixation site 6. Patient has an active, or known history of, bleeding diathesis or hypercoagulable condition 7. Patient has a contraindication to any materials to which he or she will be exposed during the EVAR procedure (i.e., Fortevo Endograft or Heli-FX EndoAnchor System materials, contrast agents) 8. Patient has a genetic connective tissue disorder (e.g., Marfan's or Ehlers-Danloe Syndromes)